Philadelphia, Pennsylvania--(Newsfile Corp. - December 22, 2025) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to ...

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who purchased securities during the specified class period, alleging misleading statements regarding the company's business and operations [1][3]. Company Overview - Telix Pharmaceuticals Ltd. is a biopharmaceutical company based in Melbourne, Australia, focusing on the development of radiopharmaceuticals for cancer treatment [2]. Allegations - The lawsuit claims that the defendants made false or misleading statements, including: - Materially overstated progress on prostate cancer therapeutic candidates [3]. - Exaggerated quality and performance of the company's supply chain and partners [3]. - Resulting statements about the company's business, operations, and prospects were allegedly false or lacked a reasonable basis [3]. Investor Information - Investors who purchased Telix securities during the class period have until January 9, 2026, to seek appointment as lead plaintiff representative [2].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. for allegedly making false or misleading statements regarding its business operations and prospects during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Telix securities from February 21, 2025, to August 28, 2025 [1][2]. - Investors have until January 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - Defendants are accused of overstating progress on prostate cancer therapeutic candidates [3]. - The quality and performance of the Company's supply chain and partners were allegedly exaggerated [3]. - As a result of these misrepresentations, statements regarding the Company's business and operations were claimed to be false or misleading [3]. Group 3: Company Background - Telix Pharmaceuticals is a biopharmaceutical company based in Melbourne, Australia, focusing on radiopharmaceutical development for cancer treatment [2].